Sign In
Buy NVAX
$10.20
-0.0100 (-0.0979%)
At Close: Jun 03, 2026
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
10:55am, Friday, 09'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
09:55am, Friday, 09'th May 2025
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
01:31pm, Thursday, 08'th May 2025
On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.
Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
11:48am, Thursday, 08'th May 2025
Novavax, Inc. (NASDAQ:NVAX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Of
Why This Shrinking Covid-19 Vaccine Stock Jumped 30%
11:12am, Thursday, 08'th May 2025
Novavax has seen its shares plummet since the pandemic because of weakening demand.
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
10:16am, Thursday, 08'th May 2025
Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago.
Novavax swings to profit on lower expenses related to COVID shots
08:06am, Thursday, 08'th May 2025
Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
08:00am, Thursday, 08'th May 2025
FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD-Utah study demonstrates that Nuvaxovid® resulted
New vaccine chief rocks pharmaceutical stocks
11:13am, Wednesday, 07'th May 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Novavax to Participate in BofA Securities 2025 Health Care Conference
08:00am, Wednesday, 07'th May 2025
GAITHERSBURG, Md. , May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.
Novavax to Report First-Quarter Earnings: Is a Beat in Store?
08:15am, Monday, 05'th May 2025
On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
08:00am, Monday, 05'th May 2025
Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will con
Novavax (NVAX) Flat As Market Gains: What You Should Know
06:50pm, Friday, 02'nd May 2025
In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
08:00am, Thursday, 01'st May 2025
GAITHERSBURG, Md. , May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Tuesday, 29'th Apr 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
